{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:37:02Z","timestamp":1785580622758,"version":"3.56.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.semarthrit.2025.152848","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:15:41Z","timestamp":1759731341000},"page":"152848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Concomitant inflammatory bowel disease impairs biologic response and increases residual symptom burden in psoriatic arthritis"],"prefix":"10.1016","volume":"75","author":[{"given":"Maria","family":"Morrone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Venerito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Giannotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Beatrice","family":"Principi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Dell","family":"Aquila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-9566","authenticated-orcid":false,"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.semarthrit.2025.152848_bib0001","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis. Longo DL","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152848_bib0002","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2025.152848_bib0003","article-title":"Extra-articular manifestations and comorbidities in psoriatic disease: a journey into the immunologic crosstalk","volume":"8","author":"Novelli","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152848_bib0004","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152848_bib0005","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/annrheumdis-2012-202143","article-title":"Psoriasis, psoriatic arthritis and increased risk of incident Crohn\u2019s disease in US women","volume":"72","author":"Li","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152848_bib0006","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials","volume":"78","author":"Schreiber","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152848_bib0007","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s10067-016-3374-y","article-title":"Gastrointestinal comorbidities in patients with psoriatic arthritis","volume":"35","author":"Zohar","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152848_bib0008","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4103\/ijd.ijd_34_22","article-title":"The importance of screening for inflammatory bowel disease in patients with psoriasis and psoriatic arthritis","volume":"67","author":"Aldana","year":"2022","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.semarthrit.2025.152848_bib0009","article-title":"Managing psoriatic arthritis with inflammatory bowel disease and\/or uveitis","volume":"8","author":"Chia","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152848_bib0010","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152848_bib0011","first-page":"52","article-title":"GRAPPA treatment recommendations: 2021 update","volume":"49","author":"Coates","year":"2022","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152848_bib0012","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152848_bib0013","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1136\/annrheumdis-2023-eular.1829","article-title":"AB1134\u2005Impact of inflammatory bowel disease on Dapsa remission in patients with psoriatic arthritis: a propensity score-matched retrospective analysis of \u201ccross\u201d multidisciplinary project patients\u2019. [CONFERENCE ABSTRACT]","volume":"82","author":"Giannotta","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152848_bib0014","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamadermatol.2022.3682","article-title":"Association between inflammatory bowel disease and both psoriasis and psoriatic arthritis: a bidirectional 2-sample mendelian randomization study","volume":"158","author":"Freuer","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152848_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003820","article-title":"Impact of biological therapy in reducing the risk of arthritis development in inflammatory bowel diseases","volume":"10","author":"Fatica","year":"2024","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152848_bib0016","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/EDE.0b013e3181577654","article-title":"The strengthening the reporting of observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"18","author":"Von Elm","year":"2007","journal-title":"Epidemiology (Fairfax)"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152848_bib0017","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.3899\/jrheum.210434","article-title":"Oligoarticular vs polyarticular psoriatic arthritis: a longitudinal study showing similar characteristics","volume":"48","author":"Gladman","year":"2021","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152848_bib0018","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152848_bib0019","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states","volume":"77","author":"Machado","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152848_bib0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152848_bib0021","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","article-title":"International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials","volume":"76","author":"Orbai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152848_bib0022","series-title":"Propensity score analysis: statistical methods and applications","author":"Guo","year":"2010"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152848_bib0023","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1097\/MIB.0000000000001169","article-title":"Prevalence and phenotype of concurrent psoriasis and inflammatory bowel disease","volume":"23","author":"Eppinga","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152848_bib0024","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/1744666X.2021.1991315","article-title":"Inflammatory bowel disease manifestations in spondyloarthritis: considerations for the clinician","volume":"17","author":"Lubrano","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.semarthrit.2025.152848_bib0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3899\/jrheum.180134","article-title":"The microbiome in psoriasis and psoriatic arthritis: joints","volume":"94","author":"Scher","year":"2018","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152848_bib0026","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.autrev.2018.01.002","article-title":"Interaction between microbiome and host genetics in psoriatic arthritis","volume":"17","author":"Chimenti","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152848_bib0027","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3390\/ijms26010121","article-title":"Key interleukins in inflammatory bowel disease\u2014A review of recent studies","volume":"26","author":"Aebisher","year":"2024","journal-title":"IJMS"},{"issue":"14","key":"10.1016\/j.semarthrit.2025.152848_bib0028","article-title":"Inflammatory cytokines in psoriatic arthritis: understanding pathogenesis and implications for treatment","volume":"24","author":"Lee","year":"2023","journal-title":"IJMS"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152848_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002533","article-title":"Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study","volume":"9","author":"Tillett","year":"2023","journal-title":"RMD Open"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152848_bib0030","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/rheumatology\/kez505","article-title":"Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis","volume":"59","author":"Iannone","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2025.152848_bib0031","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X241303316","article-title":"Inflammatory bowel disease in axial spondyloarthritis patients. Is there any specific clinical picture? Data from the RESPONDIA and REGISPONSER registries","volume":"16","author":"Llop","year":"2024","journal-title":"Therapeutic Adv Musculoskeletal"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152848_bib0032","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202135","article-title":"Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model","volume":"72","author":"Van Praet","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"10.1016\/j.semarthrit.2025.152848_bib0033","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.3748\/wjg.v21.i19.5823","article-title":"Contribution of the IL-17\/IL-23 axis to the pathogenesis of inflammatory bowel disease","volume":"21","author":"C\u0103tan\u0103","year":"2015","journal-title":"WJG"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152848_bib0034","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/mi.2008.84","article-title":"The roles of CCR6 in migration of Th17 cells and regulation of effector T-cell balance in the gut","volume":"2","author":"Wang","year":"2009","journal-title":"Mucosal Immunol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152848_bib0035","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41385-021-00476-6","article-title":"\u03b14\u03b27 expression guides B cells to front lines of defense in the gut","volume":"15","author":"Shouval","year":"2022","journal-title":"Mucosal Immunol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152848_bib0036","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.gastro.2015.10.046","article-title":"Leukocyte trafficking to the small intestine and colon","volume":"150","author":"Habtezion","year":"2016","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152848_bib0037","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41584-020-0454-9","article-title":"Revisiting the gut\u2013joint axis: links between gut inflammation and spondyloarthritis","volume":"16","author":"Gracey","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"22","key":"10.1016\/j.semarthrit.2025.152848_bib0038","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.3390\/jcm12227132","article-title":"Drug clearance in patients with inflammatory bowel disease treated with biologics","volume":"12","author":"Deyhim","year":"2023","journal-title":"JCM"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152848_bib0039","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3390\/medicina60020250","article-title":"Therapeutic drug monitoring for biologic and small-molecule therapies for inflammatory bowel disease","volume":"60","author":"Dutt","year":"2024","journal-title":"Medicina (B Aires)"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152848_bib0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/antib13010016","article-title":"Immunogenicity and loss of effectiveness of biologic therapy for inflammatory bowel disease patients due to anti-drug antibody development","volume":"13","author":"Velikova","year":"2024","journal-title":"Antibodies"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152848_bib0041","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2263209","article-title":"Low-level inflammation, immunity, and brain-gut axis in IBS: unraveling the complex relationships","volume":"15","author":"Yuan","year":"2023","journal-title":"Gut Microbes"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152848_bib0042","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1743-7075-7-79","article-title":"Gut inflammation in chronic fatigue syndrome","volume":"7","author":"Lakhan","year":"2010","journal-title":"Nutr Metab (Lond)"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152848_bib0043","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/2049463713479229","article-title":"Gut pain & visceral hypersensitivity","volume":"7","author":"Farmer","year":"2013","journal-title":"Br J Pain"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152848_bib0044","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/bmb\/ldab010","article-title":"Psychological factors associated with inflammatory bowel disease","volume":"138","author":"Eugenicos","year":"2021","journal-title":"Br Med Bull"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152848_bib0045","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41575-022-00634-6","article-title":"Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment","volume":"19","author":"Bisgaard","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.semarthrit.2025.152848_bib0046","article-title":"Psychological disorders and coping strategies in patients with Inflammatory Bowel Disease. Their impact in health-related quality of life","author":"L","year":"2023","journal-title":"Rev Esp Enferm Dig"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152848_bib0047","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.14309\/ajg.0000000000001932","article-title":"The Association between nonsteroidal anti-inflammatory drug use and inflammatory bowel disease exacerbations: a true association or residual bias?","volume":"117","author":"Cohen-Mekelburg","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152848_bib0048","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/rheumatology\/kez427","article-title":"Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment\u2014Results from 12 countries in EuroSpA","volume":"59","author":"Brahe","year":"2020","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152848_bib0049","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/annrheumdis-2021-220097","article-title":"Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration","volume":"80","author":"Lindstr\u00f6m","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225002197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225002197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:55:21Z","timestamp":1765979721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225002197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":49,"alternative-id":["S0049017225002197"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152848","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concomitant inflammatory bowel disease impairs biologic response and increases residual symptom burden in psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152848","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152848"}}